Alembic Pharma Receives US FDA Approval For Generic Macrodantin Capsules
Alembic Pharmaceuticals Limited announced that it has received final approval from the US Food & Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for nitrofurantoin capsules, USP (Macrocrystals), 25 mg, 50 mg and 100 mg.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), macrodantin capsules, 25 mg, 50 mg, and 100 mg, of Alvogen Malta Operations Ltd.Nitrofurantoin capsules, USP (Macrocrystals) is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species.Nitrofurantoin Capsules, USP (Macrocrystals), 25 mg, 50 mg and 100 mg have an estimated market size of US$ 23 million for twelve months ending March 2021 according to IQVIA.Alembic has a cumulative total of 146 ANDA approvals (128 final approvals and 18 tentative approvals) from US FDA.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!